• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Preclinical CROs Expand Operations to Shanghai

Preclinical CROs Expand Operations to Shanghai

October 27, 2008
CenterWatch Staff

China has seen significant growth in the area of drug research and development in the past few years, and this growth will continue into the fourth quarter of 2008 with the opening of two new preclinical facilities in Shanghai.

Earlier this month, preclinical contract research organization (CRO) MPI Research opened a 50,000-square-foot building in Shanghai’s Chuansha Economic Park. The new facility, a result of a recently formed joint venture between MPI Research and Shanghai Medicilion, will provide preclinical drug discovery and development services in Asia.

Preclinical research powerhouse Charles River Laboratories also announced this month plans to expand its global reach with a new 60,000-square-foot facility in Shanghai. Slated to open in early 2009, the new facility will support a growing demand from multinational pharmaceutical clients for outsourced drug development services, according to a company release. Charles River and Shanghai-based Shanghai BioExplorer formed a joint venture last year to create Charles River Preclinical Services Greater China last year. The new facility is the result of this partnership.

“As our clients make their initial forays into China, we are creating a center of excellence that embodies global best practices alongside them,” said president, chairman and CEO James Foster in a company release. “Our clients have come to appreciate and rely on the expertise Charles River brings to their drug development efforts, and the convenience of our facilities in close proximity. The same high standards of research, safety, humane care and good laboratory practices that globally distinguish Charles River are replicated in our Shanghai facility. Expanding into this arena is a marathon—not a sprint—and this facility marks the first step in our journey.”

Perhaps a testament to China’s emergence as a center for drug development and innovation, the U.S. Department of Health and Human Services will open the first overseas office of the U.S. Food and Drug Administration (FDA) in China by the end of this year. Staff will be placed in Beijing this year, with more staff scheduled to post in Shanghai and Guangzhou in 2009. The department anticipates a total of eight U.S. nationals in China by next year. The China offices are part of a larger plan to open FDA offices in China, India, Europe and Latin America by the end of 2009.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing